drugset / Trial / NCT00079833

Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome

NCT00079833

Phase 3 Completed 25 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This research study will determine if esomeprazole, when administered twice daily at 40, 80, or 120 mg doses, can control excessive stomach acid secretion.

Timeline

Start
2003-11
Primary completion
Completion
2005-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 40 mg
Subject Esomeprazole Small molecule 80 mg
Subject Esomeprazole Small molecule 120 mg